Recombinant Proteins iso9001 ISO13485
搜索
 > 【IGF-I R】重组蛋白信息

IGF-I R信息

英文名称:Insulin-like growth factor I receptor
中文名称:胰岛素样生长因子-I受体
靶点别称:IGF-I receptor,IGF1R,Insulin Like Growth Factor 1 Receptor,Insulin-Like Growth Factor I Receptor,Soluble IGF1R Variant 1,Soluble IGF1R Variant 2,CD221 Antigen,CD221,IGFIR,JTK13,IGFR,Receptor, IGF Type 1,Insulin-Like Growth Factor 1 Receptor,MGC18216
上市药物数量:6
临床药物数量:13
最高研发阶段:批准上市

IGF-I R产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
IGR-M5223
Mouse
Mouse IGF-I R / CD221 Protein, His Tag
IGR-R5224
Rat
Rat IGF-I R / CD221 Protein, His Tag
IGR-C5225
Cynomolgus
Cynomolgus IGF-I R / CD221 Protein, His Tag
IGR-H5229
Human
Human IGF-I R / CD221 Protein, His Tag
 
评论(0)
 

IGF-I R 分子别名

IGF1R,CD221,IGFR,JTK13,CD221,MGC142170,MGC142172,MGC18216

IGF-I R 分子背景

The Insulin-like Growth Factor 1 Receptor (IGF1) is also known as CD221, JTK13. and is a transmembrane receptor that is activated by IGF-1 and by the related growth factor IGF-2. It belongs to the large class of tyrosine kinase receptors. This receptor mediates the effects of IGF-1, which is a polypeptide protein hormone similar in molecular structure to insulin. IGF1R is make up of two alpha subunits and two beta subunits ,the Both the α and β subunits are synthesized from a single mRNA precursor. The precursor is then glycosylated, proteolytically cleaved, and crosslinked by cysteine bonds to form a functional transmembrane αβ chain.The α chains are located extracellularly while the β subunit spans the membrane and are responsible for intracellular signal transduction upon ligand stimulation. IGF1R have a binding site for ATP, which is used to provide the phosphates for autophosphorylation. There is a 60% homology between IGF1R and the insulin receptor. In response to ligand binding, the α chains induce the tyrosine autophosphorylation of the β chains. This event triggers a cascade of intracellular signaling that, while somewhat cell type specific, often promotes cell survival and cell proliferation.

IGF-I R 参考文献

IGF-I R上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Mecasermin (Ipsen) IGF-1; FK-780; MKN-031 批准上市 益普生 Increlex EU Laron综合征 Ipsen Pharma 2005-08-30 生长迟缓, 生长障碍, Laron综合征 详情
IGF-1 (Biogen/Pharmacia & Upjohn) 批准上市 百健, Pharmacia & Upjohn Igef Sweden 侏儒症 null 1994-01-01 侏儒症
Mecasermin (Astellas/OrphanPacific) 批准上市 Astellas Pharma Inc Somazon Japan 侏儒症, 脂肪萎缩性糖尿病, 生长激素缺乏 null 1994-10-05 脂肪萎缩性糖尿病, 侏儒症, 生长激素缺乏 详情
Teprotumumab R-1507; RG-1507; RO-4858696; HZN-001 批准上市 Genmab, 罗氏 Tepezza United States 甲状腺相关性眼病 Horizon Therapeutics Ireland 2020-01-21 甲状腺相关性眼病, 糖尿病黄斑水肿, 肉瘤, 前列腺癌, 乳腺癌, 弥漫性硬皮病 详情
Insulin aspart 门冬胰岛素 NN-1218; INA-X14; Insulin X14 批准上市 诺和诺德制药 Novolog, NovoRapid, NovoLog FlexPen, NovoMix, Fiasp, 诺和锐, NovoRapid/NovoLog Japan 糖尿病 Novo Nordisk A/S 1999-09-07 1型糖尿病, 二型糖尿病, 糖尿病 详情
Ceritinib 色瑞替尼 LDK-378; NVP-LDK378; NVP-LDK378-NX 批准上市 诺华制药 赞可达, Zykadia Mainland China 非小细胞肺癌 Novartis Europharm Ltd 2014-04-29 胃癌, 胶质母细胞瘤, 肺腺癌, 胰腺癌, 胆管上皮癌, 结直肠癌, 肝功能衰退, 间变大细胞淋巴瘤, 鳞状细胞癌, 浆细胞性肉芽肿, 食道腺癌, 非小细胞肺癌, 腺癌 详情
Insulin degludec 德谷胰岛素 NN-1250; Insulin-454 批准上市 诺和诺德制药 诺和达, Tresiba Mainland China 二型糖尿病 Novo Nordisk A/S 2012-09-28 1型糖尿病, 二型糖尿病, 糖尿病 详情
Brigatinib AP-26113 批准上市 Takeda Pharmaceutical Co Ltd, Ariad Alunbrig Japan 非小细胞肺癌 Takeda 2017-04-28 实体瘤, 转移性上皮癌, 肌纤维瘤, 间变大细胞淋巴瘤, 肺癌, 非小细胞肺癌 详情

IGF-I R临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
VPI-2690B VPI-2690B 临床二期 University Of North Carolina At Chapel Hill 糖尿病肾病 详情
124I-CPD-1023-figitumumab 124I-CPD-1028; 125I-CPD-1028; CPD-1028-[124I]; CPD-1028-[125I]; FPX-1028 临床一期 Fusion Pharma 肿瘤
BVS-857 BVS-857 临床二期 诺华制药 胰岛素抵抗, 脊髓延髓肌肉萎缩症 详情
IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) 临床一期 Sidney Kimmel Cancer Center 胶质瘤 详情
Insulin-Like Growth Factor 1 (Wright State Physicians) 临床一期 Wright State Physicians 鼻唇沟皱纹, 晒伤 详情
Dalotuzumab h7C-10; MK-0646; F-50-035 临床二期 Pierre Fabre Group 直肠癌, 胰腺癌, 多发性骨髓瘤, 神经内分泌瘤, 乳腺癌, 结直肠癌, 非小细胞肺癌 详情
Picropodophyllin PPP; AXL-1717; NSC-36407 临床二期 Axelar Ab 星形细胞瘤, 非小细胞肺癌
W-0101 (Pierre Fabre Medicament) W-0101 临床二期 Pierre Fabre Group 肿瘤 详情
BIIB-022 BIIB-022 临床一期 百健 肝细胞癌, 非小细胞肺癌 详情
IGV-001 IGV-001 临床二期 托马斯杰斐逊大学 胶质母细胞瘤 详情
Mecasermin Rinfabate SHP-607; HGT-ROP-001; rhIGF-I/rhIGFBP-3 临床二期 Insmed 努南综合征, 生长迟缓, 脑室内出血, 支气管肺发育不良, Laron综合征, 早产儿视网膜病变, 肌营养不良 详情
Conteltinib CT-707; SY-707 临床三期 首药控股(北京)有限公司, 北京赛林泰医药技术有限公司 非小细胞肺癌 详情
Ganitumab AMG-479 临床三期 安进 尤因肉瘤, 非小细胞肺癌, 转移癌, 胃肠道癌症, 肺癌, 淋巴瘤, 结直肠癌, 前列腺癌, 乳腺癌, 肠道肿瘤, 肉瘤, 小细胞肺���, 结肠癌, 胰腺癌, 直肠癌, 类癌瘤, 实体瘤, 卵巢癌 详情
CT102 CT-102 临床一期 中国人民解放军军事医学科学院放射医学研究所, 杭州天龙药业有限公司 肝细胞癌

消息提示

请输入您的联系方式,再点击提交!

确定